Vogt MR - Search Results

1

Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus.

Zhang S, Vogt MR, Oliphant T, Engle M, Bovshik EI, Diamond MS, Beasley DW. Zhang S, et al. Among authors: vogt mr. J Infect Dis. 2009 Jul 15;200(2):202-5. doi: 10.1086/599794. J Infect Dis. 2009. PMID: 19527169 Free PMC article.

2

Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step.

Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, Diamond MS. Vogt MR, et al. J Virol. 2009 Jul;83(13):6494-507. doi: 10.1128/JVI.00286-09. Epub 2009 Apr 22. J Virol. 2009. PMID: 19386704 Free PMC article.

3

Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM. Dunn MD, et al. Among authors: vogt mr. Virol J. 2010 May 12;7:95. doi: 10.1186/1743-422X-7-95. Virol J. 2010. PMID: 20462412 Free PMC article.

4

Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354.

Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG. Kaufmann B, et al. Among authors: vogt mr. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18950-5. doi: 10.1073/pnas.1011036107. Epub 2010 Oct 18. Proc Natl Acad Sci U S A. 2010. PMID: 20956322 Free PMC article.

5

Beta interferon controls West Nile virus infection and pathogenesis in mice.

Lazear HM, Pinto AK, Vogt MR, Gale M Jr, Diamond MS. Lazear HM, et al. Among authors: vogt mr. J Virol. 2011 Jul;85(14):7186-94. doi: 10.1128/JVI.00396-11. Epub 2011 May 4. J Virol. 2011. PMID: 21543483 Free PMC article.

6

Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.

Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS. Vogt MR, et al. J Virol. 2011 Nov;85(22):11567-80. doi: 10.1128/JVI.05859-11. Epub 2011 Sep 14. J Virol. 2011. PMID: 21917960 Free PMC article.

7

Current Understanding of Humoral Immunity to Enterovirus D68.

Vogt MR, Crowe JE Jr. Vogt MR, et al. J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S49-S53. doi: 10.1093/jpids/piy124. J Pediatric Infect Dis Soc. 2018. PMID: 30590621 Review.

8

Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease.

Vogt MR, Fu J, Kose N, Williamson LE, Bombardi R, Setliff I, Georgiev IS, Klose T, Rossmann MG, Bochkov YA, Gern JE, Kuhn RJ, Crowe JE Jr. Vogt MR, et al. Sci Immunol. 2020 Jul 3;5(49):eaba4902. doi: 10.1126/sciimmunol.aba4902. Sci Immunol. 2020. PMID: 32620559 Free PMC article.

9

A Severe Case of Enterovirus A71 Acute Flaccid Myelitis With Encephalitis.

Passiak BS, Vogt MR, Wolf M, Sarma A, Vu N. Passiak BS, et al. Among authors: vogt mr. J Pediatric Infect Dis Soc. 2020 Dec 31;9(6):777-780. doi: 10.1093/jpids/piaa067. J Pediatric Infect Dis Soc. 2020. PMID: 32535628 No abstract available.

10

A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models.

Warner NL, Archer J, Park S, Singh G, McFadden KM, Kimura T, Nicholes K, Simpson A, Kaelber JT, Hawman DW, Feldmann H, Khandhar AP, Berglund P, Vogt MR, Erasmus JH. Warner NL, et al. Among authors: vogt mr. Sci Transl Med. 2024 Aug 7;16(759):eadi1625. doi: 10.1126/scitranslmed.adi1625. Epub 2024 Aug 7. Sci Transl Med. 2024. PMID: 39110777

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters